Atorvastatin strontium

阿托伐他汀锶

Report date: 2026/03/30 17:02:26

Base Information

Drug NameAtorvastatin strontium
Drug Alias NameNewvast
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitors
TargetsHMG-CoA reductase
Therapy Area/IndicationsHyperlipidemiasHypertensionSubarachnoid Hemorrhage
Global Approved IndicationsHyperlipidemias
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2008/01/01
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdThe George Institute For Global Health
Inactive CompaniesYale University
Active IndicationsHyperlipidemiasSubarachnoid Hemorrhage
Inactive IndicationsHypertension

Other Information

ATC CodeC10BA05
Related LinksN/A